BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, today announced the appointment of Phil Tinmouth as Chief Business Officer and Siang Chin as General Counsel.
Phil joins Mammoth from Pardes Biosciences, where he led business development and strategic initiatives as Chief Business and Strategy Officer. Phil’s decades of biopharmaceutical industry experience include a near 20-year career at Vertex Pharmaceuticals, where he played a key role in helping drive the company’s growth. As Vice President and Head of Business Development, Phil built a dynamic team of deal and alliance professionals that executed approximately 30 external deals and collaborations, yielding multiple clinical candidates. While at Vertex, Phil served on multiple committees and teams as the company grew from roughly 300 employees with a market cap of $800 million to well over 3,000 employees and a market cap of more than $50 billion. Prior to Vertex, Phil was a senior manager at Bain & Company in Boston where he advised pharma and biotech clients on growth strategies for over five years. Phil received his bachelor’s degree in mechanical engineering from Queen’s University in Canada, and his MBA from Harvard Business School.
“As Chief Business Officer, I’m eager to contribute to Mammoth’s disruptive efforts to create an expansive portfolio of life-changing, CRISPR-based technologies, helping to reimagine therapeutics, diagnostics, and beyond,” said Phil. “Mammoth has tremendous momentum and a long-term roadmap for differentiated value creation. I’m honored to join this talented, innovative group of CRISPR trailblazers.”
Mammoth Biosciences also announced today the appointment of Siang Chin as General Counsel. Siang has an extensive career guiding legal strategy at leading biotechnology, life sciences, and medtech companies — successfully executing transformational transactions and navigating complex regulatory and intellectual property matters. Siang was previously General Counsel of Affymetrix, Inc., where she was part of an executive team that drove growth, profitability, and the company’s acquisition by Thermo Fisher Scientific in 2016. In her most recent position as Vice President and Assistant General Counsel at Intuitive Surgical, she led and grew the corporate, commercial, and compliance legal functions and was instrumental in executing the company’s strategic acquisitions, joint ventures, and key collaborations. Siang received her Bachelor of Laws from King’s College London and her Master of Laws from Georgetown University.
“I am excited to join the Mammoth executive team at this time of growth and innovation,” said Siang. “With an outstanding foundation in science, Mammoth is well positioned to capitalize on the capabilities of its proprietary technology.”
“We’re thrilled in welcoming Phil and Siang to lead two important functions, as they both bring business acumen and deep, senior-level industry experience,” said Trevor Martin, Ph.D., co-founder and Chief Executive Officer of Mammoth Biosciences. “Phil’s track record of driving key strategic collaborations and Siang’s diverse legal expertise will help prepare us for the evolving needs of our company and industry.”
About Mammoth Biosciences
Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop one-time treatments through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and Casɸ enzymes, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense, and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC.